Total Payments
$664,935
2024 Payments
$29,486
Companies
20
Transactions
699
Medicare Patients
475
Medicare Billing
$88,804
Payment Breakdown by Category
Other$302,246 (45.5%)
Consulting$243,828 (36.7%)
Research$63,820 (9.6%)
Travel$34,079 (5.1%)
Food & Beverage$20,682 (3.1%)
Education$281.50 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $302,246 | 106 | 45.5% |
| Consulting Fee | $243,828 | 61 | 36.7% |
| Unspecified | $63,820 | 66 | 9.6% |
| Travel and Lodging | $34,079 | 156 | 5.1% |
| Food and Beverage | $20,682 | 304 | 3.1% |
| Education | $281.50 | 6 | 0.0% |
Payments by Type
General
$601,116
633 transactions
Research
$63,820
66 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Biogen, Inc. | $280,254 | 258 | $0 (2024) |
| GENZYME CORPORATION | $79,374 | 86 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $67,112 | 117 | $0 (2024) |
| EMD Serono, Inc. | $65,276 | 85 | $0 (2024) |
| Genentech USA, Inc. | $50,404 | 34 | $0 (2022) |
| Celgene Corporation | $42,827 | 45 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $34,151 | 21 | $0 (2024) |
| Novartis Pharma AG | $11,112 | 4 | $0 (2018) |
| F. Hoffmann-La Roche AG | $9,579 | 10 | $0 (2024) |
| AbbVie Inc. | $9,244 | 5 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $29,486 | 36 | GENZYME CORPORATION ($11,434) |
| 2023 | $52,609 | 65 | EMD Serono, Inc. ($28,228) |
| 2022 | $73,976 | 88 | EMD Serono, Inc. ($20,773) |
| 2021 | $62,675 | 43 | Biogen, Inc. ($19,025) |
| 2020 | $66,142 | 70 | Biogen, Inc. ($19,300) |
| 2019 | $94,129 | 95 | Biogen, Inc. ($52,143) |
| 2018 | $112,494 | 111 | Biogen, Inc. ($53,208) |
| 2017 | $173,425 | 191 | Biogen, Inc. ($101,784) |
All Payment Transactions
699 individual payment records from CMS Open Payments — Page 1 of 28
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/11/2024 | Biogen, Inc. | VUMERITY (Drug) | Food and Beverage | In-kind items and services | $136.00 | General |
| Category: Neurology | ||||||
| 12/03/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $119.32 | General |
| 11/20/2024 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $5.45 | General |
| Category: Neurology | ||||||
| 11/08/2024 | GENZYME CORPORATION | — | Consulting Fee | Cash or cash equivalent | $10,288.00 | General |
| 11/08/2024 | GENZYME CORPORATION | — | Travel and Lodging | In-kind items and services | $413.38 | General |
| 11/08/2024 | GENZYME CORPORATION | — | Food and Beverage | In-kind items and services | $265.00 | General |
| 11/08/2024 | GENZYME CORPORATION | — | Travel and Lodging | In-kind items and services | $202.92 | General |
| 11/08/2024 | GENZYME CORPORATION | — | Travel and Lodging | In-kind items and services | $108.11 | General |
| 11/06/2024 | EMD Serono, Inc. | Mavenclad (Drug) | Food and Beverage | Cash or cash equivalent | $119.93 | General |
| Category: Neurology | ||||||
| 10/24/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $122.71 | General |
| 09/18/2024 | Biogen, Inc. | TYSABRI (Biological), VUMERITY | Food and Beverage | In-kind items and services | $76.18 | General |
| Category: Neurology | ||||||
| 09/11/2024 | E.R. Squibb & Sons, L.L.C. | ZEPOSIA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,759.00 | General |
| Category: Neuroscience | ||||||
| 09/05/2024 | E.R. Squibb & Sons, L.L.C. | ZEPOSIA (Drug) | Travel and Lodging | Cash or cash equivalent | $58.00 | General |
| Category: Neuroscience | ||||||
| 09/05/2024 | E.R. Squibb & Sons, L.L.C. | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $45.09 | General |
| Category: Neuroscience | ||||||
| 09/05/2024 | E.R. Squibb & Sons, L.L.C. | ZEPOSIA (Drug) | Travel and Lodging | Cash or cash equivalent | $19.83 | General |
| Category: Neuroscience | ||||||
| 08/29/2024 | GENZYME CORPORATION | — | Food and Beverage | In-kind items and services | $79.20 | General |
| 08/28/2024 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $5.77 | General |
| Category: Neurology | ||||||
| 08/21/2024 | E.R. Squibb & Sons, L.L.C. | ZEPOSIA (Drug) | Travel and Lodging | Cash or cash equivalent | $1,228.06 | General |
| Category: Neuroscience | ||||||
| 08/21/2024 | E.R. Squibb & Sons, L.L.C. | ZEPOSIA (Drug) | Travel and Lodging | Cash or cash equivalent | $648.77 | General |
| Category: Neuroscience | ||||||
| 08/21/2024 | E.R. Squibb & Sons, L.L.C. | ZEPOSIA (Drug) | Travel and Lodging | Cash or cash equivalent | $261.21 | General |
| Category: Neuroscience | ||||||
| 08/21/2024 | E.R. Squibb & Sons, L.L.C. | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $35.40 | General |
| Category: Neuroscience | ||||||
| 07/17/2024 | GENZYME CORPORATION | — | Food and Beverage | In-kind items and services | $77.33 | General |
| 07/10/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $95.85 | General |
| 07/02/2024 | Novartis Pharmaceuticals Corporation | MAYZENT (Drug) | — | Cash or cash equivalent | $2,409.44 | Research |
| Study: CBAF312AUS02 • Category: Neurology | ||||||
| 06/30/2024 | F. Hoffmann-La Roche AG | Enspryng (Biological) | — | In-kind items and services | $728.21 | Research |
| Study: Development and Validation of a Claims-Based Algorithm to Identify Patients With Neuromyelitis Optica Spectrum Disorder • Category: Immunology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH HEOR RESEARCH | NOVARTIS PHARMACEUTICALS CORPORATION | $10,471 | 11 |
| PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH ARZERRA RESEARCH | Novartis Pharmaceuticals Corporation | $8,500 | 1 |
| RESEARCH RELATED PUBLICATIONS SUPPORT | Novartis Pharmaceuticals Corporation | $7,111 | 8 |
| Efficacy and Safety of Daclizumab in Participants With RRMS Switching From Natalizumab | Biogen, Inc. | $6,988 | 2 |
| Publication support research related | Novartis Pharma AG | $5,772 | 1 |
| RESEARCH RELATED PUBLICATIONS SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $3,091 | 8 |
| An international, multi-center, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of two year treatment with 7 mg once daily and 14 mg once daily v | SANOFI-AVENTIS U.S. LLC | $2,777 | 6 |
| TESTING A CLAIMS-BASED ALGORITHM TO IDENTIFY PATIENTS WITH NEUROMYELITIS OPTICA SPECTRUM DISORDER | F. Hoffmann-La Roche AG | $2,528 | 3 |
| CBAF312AUS02 | Novartis Pharmaceuticals Corporation | $2,409 | 1 |
| COMB157G2301 | Novartis Pharmaceuticals Corporation | $2,169 | 1 |
| EXPLORING THE SAFETY AND TOLERABILITY OF CONVERSION TO DOSE TITRATED SIPONIMOD IN PATIENTS WITH RELAPSING FORMS OF MULTIPLE SCLEROSIS A 6 MONTH OPEN LABEL MULTI CENTER PHASE III B STUDY EXPANDED | Novartis Pharmaceuticals Corporation | $2,083 | 1 |
| Tecfidera and the Gut Microbiota (TECONGUT) NCT02471560 | Biogen, Inc. | $1,521 | 8 |
| USING COGNITIVE INTERVIEWS TO DEVELOP A CONCEPTUAL CLAIMS-BASED ALGORITHM TO IDENTIFY PATIENTS WITH NEUROMYELITIS OPTICA SPECTRUM DISORDER | F. Hoffmann-La Roche AG | $1,442 | 2 |
| A MULTICENTER RANDOMIZED DOUBLE BLIND PARALLEL GROUP PLACEBO CONTROLLED VARIABLE TREATMENT DURATION STUDY EVALUATING THE EFFICACY AND SAFETY OF SIPONIMOD BAF312 IN PATIENTS WITH SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS | Novartis Pharmaceuticals Corporation | $1,200 | 1 |
| Pacific Northwest MS Registry | GENZYME CORPORATION | $1,106 | 2 |
| A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Design Study to Evaluate the Efficacy and Safety of Teriflunomide in Reducing the Frequency of Relapses and Delaying the Accumulation of | SANOFI-AVENTIS U.S. LLC | $1,064 | 3 |
| PNWMS Registry | GENZYME CORPORATION | $1,039 | 1 |
| Development and Validation of a Claims-Based Algorithm to Identify Patients With Neuromyelitis Optica Spectrum Disorder | F. Hoffmann-La Roche AG | $728.21 | 1 |
| Safety and Efficacy of Teriflunomide (HMR1726) in Multiple Sclerosis with Relapses | GENZYME CORPORATION | $618.46 | 1 |
| RESEARCH RELATED PUBLICATION SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $558.58 | 1 |
| TeriRADAR | GENZYME CORPORATION | $401.03 | 1 |
| TERI-PRO: A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of Teriflunomide Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple | SANOFI-AVENTIS U.S. LLC | $180.00 | 1 |
| Comparing Quality of Life Between People Who Use Injectable Disease-Modifying Therapies and Those Who Switch to Oral Therapies: A Study From the Pacific Northwest Multiple Sclerosis (PNWMS) Registery | GENZYME CORPORATION | $63.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 2 | 107 | 201 | $114,236 | $23,123 |
| 2022 | 2 | 105 | 174 | $99,528 | $21,234 |
| 2021 | 2 | 122 | 200 | $115,099 | $23,961 |
| 2020 | 3 | 141 | 225 | $91,294 | $20,486 |
Total Patients
475
Total Services
800
Medicare Billing
$88,804
Procedure Codes
9
All Medicare Procedures & Services
9 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 83 | 164 | $98,400 | $20,062 | 20.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 24 | 37 | $15,836 | $3,061 | 19.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 84 | 148 | $88,504 | $18,717 | 21.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 21 | 26 | $11,024 | $2,517 | 22.8% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 95 | 169 | $101,738 | $21,082 | 20.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 27 | 31 | $13,361 | $2,880 | 21.6% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 76 | 136 | $63,104 | $13,223 | 21.0% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2020 | 37 | 47 | $13,658 | $3,953 | 28.9% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 28 | 42 | $14,532 | $3,311 | 22.8% |
About Dr. Stanley Cohan, M.D
Dr. Stanley Cohan, M.D is a Neurology healthcare provider based in Portland, Oregon. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/31/2007. The National Provider Identifier (NPI) number assigned to this provider is 1972788644.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Stanley Cohan, M.D has received a total of $664,935 in payments from pharmaceutical and medical device companies, with $29,486 received in 2024. These payments were reported across 699 transactions from 20 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($302,246).
As a Medicare-enrolled provider, Cohan has provided services to 475 Medicare beneficiaries, totaling 800 services with total Medicare billing of $88,804. Data is available for 4 years (2020–2023), covering 9 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Location Portland, OR
- Active Since 12/31/2007
- Last Updated 11/15/2021
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1972788644
Products in Payments
- TYSABRI (Biological) $113,864
- AUBAGIO (Drug) $57,285
- ZEPOSIA (Drug) $56,352
- TECFIDERA (Drug) $45,695
- OCREVUS (Biological) $31,445
- ZINBRYTA (Biological) $27,795
- MAYZENT (Drug) $23,904
- Non-Covered Product (Drug) $23,880
- Mavenclad (Drug) $20,145
- VUMERITY (Drug) $14,901
- MAVENCLAD (Drug) $13,577
- ARZERRA (Drug) $11,250
- GILENYA (Drug) $10,949
- KESIMPTA (Drug) $8,572
- Ozanimod (Drug) $8,539
- DISEASE STATE (Drug) $6,968
- FTY720D (Drug) $5,339
- Enspryng (Biological) $4,698
- Tysabri (Biological) $4,386
- LEMTRADA (Drug) $2,120
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Portland
Kyle Smoot, M.d, M.D
Neurology — Payments: $944,765
Neurology $944,765
Dr. Chafic Karam, M.d, M.D
Neurology — Payments: $647,064
Neurology $647,064
Dr. John Dolan, D.o, D.O
Neurology — Payments: $550,588
Neurology $550,588
Kiren Kresa-Reahl, M.d, M.D
Neurology — Payments: $421,575
Neurology $421,575
Matthew Brodsky, Md, MD
Neurology — Payments: $244,252
Neurology $244,252
David Spencer, Md, MD
Neurology — Payments: $101,259
Neurology $101,259